



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/</u> <u>Verified</u>
LGII1 Ab IgG Screen by IFA, CSF	Detected *		[< 1:1]	19-260-900016	17-Sep-19	17-Sep-19	17-Sep-19
LGII1 Ab IgG Titer by IFA, CSF	1:80 *		[< 1:1]	19-260-900016	07:52:00	07:52:00	07:58:07
					17-Sep-19	17-Sep-19	17-Sep-19
					07:52:00	07:52:00	07:58:14

17-Sep-19 07:52:00 LGII1 Ab IgG Screen by IFA, CSF
 LGII1 Antibody, IgG is detected. Titer results to follow.

17-Sep-19 07:52:00 LGII1 Ab IgG Screen by IFA, CSF:
 INTERPRETIVE INFORMATION: LGII1 Ab IgG w/Reflex to Titer, CSF

Leucine-rich, glioma-inactivated 1 protein (LGII1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGII1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGII1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGII1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes leucine-rich, glioma-inactivated 1 protein (LGII1) transfected cell lines for the detection and semi-quantification of the LGII1 IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

17-Sep-19 07:52:00 LGII1 Ab IgG Titer by IFA, CSF:
 INTERPRETIVE INFORMATION: LGII1 Ab Titer IgG by IFA, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab